Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 12/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764777 | 0.86 | PIK3C3 (1.00) | PIK3C3GSK3BNPY5R | |
| SCHEMBL21612168 | 0.86 | PIK3C3 (0.65) | PIK3C3ABL1GSK3BMAPK14 | |
| SCHEMBL20765638 | 0.85 | PIK3C3 (0.64) | PIK3C3ABL1 | |
| SCHEMBL20774910 | 0.83 | PIK3C3 (0.61) | PIK3C3ABL1MAPK14 | |
| SCHEMBL20765267 | 0.82 | PIK3C3 (0.74) | PIK3C3ABL1GSK3BMAPK14 | |
| SCHEMBL20774929 | 0.80 | PIK3C3 (0.57) | PIK3C3ABL1GSK3BMAPK8MAPK10 | |
| SCHEMBL24469456 | 0.78 | PIK3C3 (0.66) | PIK3C3ABL1 | |
| SCHEMBL20764787 | 0.76 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL29035853 | 0.76 | PIK3C3 (0.63) | PIK3C3ABL1GSK3BMAPK8MAPK10 | |
| SCHEMBL20765764 | 0.74 | PIK3C3 (0.63) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117083064-A | Pyridinylpyridone derivatives as VPS34 inhibitors for the treatment of viral infections | 德西费拉制药有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| US-11801238-B2 | Anti-viral activity of VPS34 inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-10-31 | — | — | US | claimed |
| EP-4251152-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3672941-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | claimed |
| CN-111094244-A | Pyridylpyridone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-09-17 | — | — | US | disclosed |
| EP-3672941-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111094244-A | Pyridylpyridone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885ABL1 1056/4885CNR2 3953/4885 |
| US-11801238-B2 | Anti-viral activity of VPS34 inhibitors | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885ABL1 1997/4885CNR2 4793/4885 |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885ABL1 1997/4885CNR2 4793/4885 |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3788/4885ABL1 2389/4885CNR2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.